News and Publications

Sign up to receive the latest news and updates from NervGen
News Releases

Filter by Year:

arrow&v
NervGen Pharma Completes Share Issuance to Drug Manufacturing Partner CSBio

2019.11.21

NervGen Receives Investment from Drug Manufacturing Partner

2019.11.18

NervGen Pharma Expands Platform into Alzheimer's Disease/NervGen Pharma's NVG-291 Compound on Track to Begin Phase 1 in Q1 2020

2019.10.28

NervGen Announces Clinical Development Plan for the Treatment of Nerve Damage and Neurodegenerative Diseases and Results of Annual General Meeting of Shareholders

2019.09.06

NervGen Pharma's Multiple Sclerosis Development Program Targeting Nerve Remylenation Supported by Publication of Independent Peer Reviewed Paper

2019.07.10

NervGen Amends Investor Relations Agreement

2019.07.05

NervGen Launches Multiple Sclerosis Program Targeting Nerve Remyelination

2019.06.26

NervGen Announces Upgrade to the OTCQX Best Market in the U.S.

2019.06.10

NervGen Presenting at 9th Annual LD Micro Invitational

2019.06.04

NervGen Engages Torrey Hills Capital for Investor Relations

2019.06.03

NervGen Appoints Dr. Denis Bosc as VP, Manufacturing and Paul Brennan Joins as Business Advisor

2019.05.30

NervGen Commences Trading on OTCQB and Engages Market Maker

2019.05.03

NervGen to Ring the Opening Bell of Toronto Stock Exchange and Closes Private Placement

2019.05.01

Patent Estate Grows with the Addition of US Patents for its Groundbreaking Nerve Regeneration Technology

2019.04.24

NervGen Increases Private Placement to $740,000

2019.04.23

NervGen Appoints Amy Franke as VP, Clinical Operations

2019.04.01

NervGen Announces $500,000 Private Placement

2019.03.14

NervGen Completes $10 Million IPO - Shares to Commence Trading on TSX-V on March 15, 2019 Under Symbol "NGEN"

2019.03.13

 
Publications in Scientific Journals

Filter by Year:

arrow&v
ScienceDirect
Modulating Proteoglycan Receptor PTPσ Using Intracellular Sigma Peptide Improves Remyelination and Functional Recovery in Mice with Demyelinated Optic Chiasm
Independent validation and demonstration of ISP treatment results in decreased demyelination, reduced astrogliosis and oligodendrocytes generation leading to enhanced remyelination, improvement in optic pathway integrity and visual acuity in LPC induced demyelination multiple sclerosis (MS) mouse model

2019.07.02

Annals of Biomedical Engineering
Automated Gait Analysis Detects Improvements After Intracellular Peptide Administration in a Rat Hemisection Model of Spinal Cord Injury
Independent validation and demonstration of ISP treatment results in functional improvement in locomotor recovery in rat spinal cord injury model using a new quantitative measurement technique alongside existing behavioral analysis

2019.01.09

 
Articles

Filter by Year:

arrow&v
Asia-Pacific Biotech News
Emerging Treatments for Spinal Cord Damage
Can damaged nerves regenerate?

2019.08.27

Laboratory News
A Real Growing Concern
Dr. Jerry Silver, Professor of Neurosciences at Case Western University, discusses emerging treatments for spinal cord injury.

2019.06.01

BioSpace
Injectable Peptide Might Help Spinal Cord Injury Patients Walk Again
Summarizes how NervGen's technology may make it possible to restore lost functions in spinal cord injury patients, moving toward clinical trials in early 2020.

2019.05.19

Scientia
Spinal Cord Damage and Emerging Treatments
Dr Silver and his team at Case Western University have teamed up with NervGen Pharma, whose vision is to restore life’s potential to patients by creating innovative solutions for the treatment of nerve damage. Together, they have identified an ISP analogue known as NVG-291 to treat human patients. It is their hope that this technology can improve the lives for the many people living with debilitating nerve damage.

2019.02.05

 
Media

Filter by Year:

arrow&v
BioPub
BioPub in Conversation with NervGen Pharma
BioPub Webcast with Dr. Jerry Silver, Dr. Harold Punnett, and Dr. Ernest Wong. Dr. Marc DePaul joins to present NervGen's technology.

2019.10.31

HealthProRadio
Jerry Silver on HealthProRadio
Dr. Jerry Silver's interview by Health Professional Radio, an internet-only media network

2019.09.24

Price of Business
Harold Punnett on the Price of Business Show
Dr. Harold Punnett's interview on The Price of Business, a nationally syndicated show on USA Business Radio.

2019.08.22

OTC
OTC Virtual Investor Conference Webcast
Dr. Ernest Wong Presented at OTC's Virtual Investor Conference on July 11, 2019 at 10:30a.m. ET

2019.07.11

BioPub
BioPub Webcast about NervGen Pharma
BioPub Webcast with Dr. Ernest Wong, CEO of NervGen, and Dr. Jerry Silver, Co-Inventor and Scientific Advisor of NervGen

2019.05.10

Price of Business
Jerry Silver on the Price of Business Show
Kevin Price Interviews Dr. Jerry Silver on The Price of Business, a nationally syndicated show on USA Business Radio.

2019.03.04

 

© 2019

TSX.V: NGEN

OTCQX: NGENF

Website last updated November 21, 2019. The information posted was accurate at the time of posting, but may be superseded by subsequent disclosures.  

This website may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward looking statements in light of new information or future events. You should also review our most recent filings on SEDAR (www.sedar.com) for a more complete discussion of these factors and other risks, particularly under the heading “Risk Factors.”